Sacubitrilat is an active metabolite of sacubitril and functions as a neprilysin inhibitor. It plays a key role in the treatment of heart failure by enhancing the body’s natural protective systems. By inhibiting neprilysin, sacubitrilat increases levels of beneficial peptides such as natriuretic peptides, bradykinin, and substance P. These substances promote vasodilation, reduce blood pressure, increase sodium excretion, and decrease fluid retention. It is used in combination with valsartan (as part of the drug sacubitril/valsartan) for the management of chronic heart failure, particularly in patients with reduced ejection fraction. This combination has been shown to reduce the risk of cardiovascular death and hospitalization compared to traditional therapies like ACE inhibitors. The drug is typically prescribed when heart failure remains symptomatic despite standard therapy.